4//SEC Filing
Astor Andrew 4
Accession 0000914190-19-000337
CIK 0001196298other
Filed
Aug 21, 8:00 PM ET
Accepted
Aug 22, 4:37 PM ET
Size
13.7 KB
Accession
0000914190-19-000337
Insider Transaction Report
Form 4
NEPHROS INCNEPH
Astor Andrew
Chief Financial Officer
Transactions
- Purchase
Common Stock
2019-08-22$6.97/sh+1,500$10,455→ 60,710 total
Holdings
- 45,079
Stock Option (right to buy)
Exercise: $4.14Exp: 2027-02-13→ Common Stock (45,079 underlying) - 32,567
Stock Option (right to buy)
Exercise: $2.64Exp: 2027-05-01→ Common Stock (32,567 underlying) - 22,223
Stock Option (right to buy)
Exercise: $5.85Exp: 2028-12-19→ Common Stock (22,223 underlying) - 14,815
Warrants (right to buy)
Exercise: $2.70From: 2017-03-17Exp: 2022-03-17→ Common Stock (14,815 underlying) - 5,556
Stock Option (right to buy)
Exercise: $4.50Exp: 2027-12-20→ Common Stock (5,556 underlying)
Footnotes (5)
- [F1]The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.9675 to $6.9725. The reporting person undertakes to provide the Company, any security holder of the Company. or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F2]On 2/13/17, the Reporting Person was granted an option to purchase up to 64,399 shares of common stock of the Company. Options to purchase 8,049 shares vested on 2/13/18; options to purchase 24,150 shares vest quarterly in 12 equal amounts commencing on 5/13/18; options to purchase 12,880 shares vested upon approval of listing of the Company's common stock on the Nasdaq Stock Market; options to purchase 6,440 shares will vest, if ever, on 2/1 following the Company's first completed fiscal year in which annual revenue exceeds $6,000,000; and options to purchase 12,880 shares will vest, if ever, on 2/1 following the Company's first completed fiscal year in which annual revenue exceeds $10,000,000.
- [F3]On 5/1/17, the Reporting Person was granted an option to purchase up to 46,525 shares of common stock of the Company. Options to purchase 5,815 shares vested on 5/1/18; options to purchase 17,447 shares vest quarterly in 12 equal amounts commencing on 7/1/18; options to purchase 4,655 shares will vest, if ever, on 2/1 following the Company's first completed fiscal year in which annual revenue exceeds $6,000,000; options to purchase 9,305 shares will vest, if ever, on 2/1 following the Company's first completed fiscal year in which annual revenue exceeds $10,000,000; and options to purchase 9,305 shares vested upon approval of listing of the Company's common stock on the Nasdaq Stock Market.
- [F4]On 12/20/17, the Reporting Person was granted an option to purchase 5,556 shares of common stock of the Company. Options to purchase 1,389 shares vested on 12/20/18 and options to purchase 4,167 shares vest quarterly in 12 equal amounts commencing on 3/20/19.
- [F5]On 12/19/18, the Reporting Person was granted an option to purchase 22,223 shares of common stock of the Company. Options to purchase 5,555 shares vest on 12/19/19 and options to purchase 16,668 shares vest quarterly in 12 equal amounts commencing on 3/19/20.
Documents
Issuer
NEPHROS INC
CIK 0001196298
Entity typeother
Related Parties
1- filerCIK 0001698052
Filing Metadata
- Form type
- 4
- Filed
- Aug 21, 8:00 PM ET
- Accepted
- Aug 22, 4:37 PM ET
- Size
- 13.7 KB